Therefore, m6A-related protein inhibitors or activators are mainly used in preclinical experimental studies and there is no researches applying inhibitors or activators of m6A-related proteins on ESCC patients. This evidence concerns the gene METTL3 and esophageal squamous cell carcinoma.